4 results
Search Results
Now showing 1 - 4 of 4
Article Citation - WoS: 10Citation - Scopus: 12Detection of Viruses by Probe-Gated Silica Nanoparticles Directly From Swab Samples(Elsevier, 2022) Tuna, Bilge Guvenc; Durdabak, Dilara Buse; Ercan, Meltem Kazak; Dogan, Soner; Kavruk, Murat; Dursun, Ali Dogan; Ozalp, Veli CengizViral infection has been one of the major health issues for human life. The real-time reverse transcription polymerase chain reaction (RT-PCR)-based detection has primarily been used for virus detection as a highly reliable procedure. However, it is a relatively long and multi-stage process. In addition, required skilled personnel and complex instrumentation presents difficulties in large scale monitoring efforts. Therefore, we report here a direct and fast detection method for CoV-2 genome as applied in the nose-throat swab samples without any further processing. The detection principle is based on fluorescein-loaded mesoporous silica nanoparticles capped by specific gene sequences probes immobilized on the surface of the nanoparticles. Upon hybridization with the target viral genome, the fluorescein molecules were released from the mesopores. Testing with synthetic oligonucleotides, the NSP12 gene-based detection resulted in a strong signal. Target detection time could be optimized to 15 min and the limit of detection was 1.4 RFU with 84% sensitivity with clinical samples (n = 43).Article Biotechnological Preparedness for Novel Pandemics: Diagnostic Performance of IVDS Against SARS-CoV(Wiley, 2025) Kavruk, Murat; Ercan, Meltem; Borsa, Baris Ata; Ozalp, Veli Cengiz; Hernandez, Frank J.Although the COVID-19 pandemic has created many challenges and negative impacts around the world, some of which will persist into the future, its technological challenge has created a unique opportunity in a globalized world. It is a rare event that almost all of humanity to be directed towards a single goal and to try to produce solutions, but the necessity of a similar global action in the future has begun to enter the agenda again. The predictions made on the basis of countries and institutions against the possibility of a pandemic, which is defined as Disease X, are shaped by the experience of the COVID-19 pandemic. Technologically, one of the know-how we have gained in this pandemic is the performance of IVD and test systems in terms of quality and quantity. A comprehensive analysis of the products produced by combining biotechnology with different strategies has not been conducted. In this context, we have analyzed the technical preferences, limitations, and other performance parameters of IVDs and test kits that could be developed against a future Disease X. The performance parameters of 2,882 biotechnological products listed for use in the European Union have been analyzed, and areas that could be targeted for increased effectiveness have been identified. Our study is the first of its kind in this field and can serve as a guide for those who want to work on detection methods, diagnostics, and novel technologies for deployment in future pandemics.Article Citation - WoS: 11Citation - Scopus: 11Impact of Vaccination on the Presence and Severity of Symptoms in Hospitalized Patients With an Infection of the Omicron Variant (b.1.1.529) of the Sars-Cov (subvariant Ba.1)(Elsevier Sci Ltd, 2023) Beraud, Guillaume; Bouetard, Laura; Civljak, Rok; Michon, Jocelyn; Tulek, Necla; Lejeune, Sophie; Epaulard, OlivierObjectives: The emergence of SARS-CoV-2 variants raised questions about the extent to which vaccines designed in 2020 have remained effective. We aimed to assess whether vaccine status was associated with the severity of Omicron SARS-CoV-2 infection in hospitalized patients.Methods: We conducted an international, multi-centric, retrospective study in 14 centres (Bulgaria, Croatia, France, and Turkey). We collected data on patients hospitalized for >= 24 hours between 1 December 2021 and 3 March 2022 with PCR-confirmed infection at a time of exclusive Omicron circu-lation and hospitalization related or not related to the infection. Patients who had received prophylaxis by monoclonal antibodies were excluded. Patients were considered fully vaccinated if they had received at least two injections of either mRNA and/or ChAdOx1-S or one injection of Ad26.CoV2-S vaccines. Results: Among 1215 patients (median age, 73.0 years; interquartile range, 57.0-84.0; 51.3% men), 746 (61.4%) were fully vaccinated. In multivariate analysis, being vaccinated was associated with lower 28 -day mortality (Odds Ratio [95% Confidence Interval] (OR [95CI]) = 0.50 [0.32-0.77]), intensive care unit admission (OR [95CI] = 0.40 [0.26-0.62]), and oxygen requirement (OR [95CI] = 0.34 [0.25-0.46]), independent of age and comorbidities. When co-analysing these patients with Omicron infection with 948 patients with Delta infection from a study we recently conducted, Omicron infection was associated with lower 28-day mortality (OR [95CI] = 0.53 [0.37-0.76]), intensive care unit admission (OR [95CI] = 0.19 [0.12-0.28]), and oxygen requirements (OR [95CI] = 0.50 [0.38-0.67]), independent of age, comorbidities, and vaccination status.Discussion: Originally designed vaccines have remained effective on the severity of Omicron SARS-CoV-2 infection. Omicron is associated with a lower risk of severe forms, independent of vaccination and pa-tient characteristics. Guillaume Beraud, Clin Microbiol Infect 2023;29:642 (c) 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).Article Comparison of SARS-CoV IgG Responses in Hemodialysis Patients and Healthcare Workers After COVID-19 Vaccination(Frontiers Media S.A., 2025) Ozturk, Hakki; Ozsoy, Metin; Tuna, Aysegul; Varlibas, Artuner; Cesur, Salih; Aksoy, Altan; Demir, Mehmet EminAim: This study aimed to compare SARS-CoV-2 IgG antibody levels in hemodialysis (HD) patients and healthcare workers (HCWs) after COVID-19 vaccination and to identify factors influencing these levels. Materials and methods: A total of 193 participants were included: 104 HD patients and 89 age- and sex-matched HCWs as controls. All had completed a primary COVID-19 vaccination series (two doses of CoronaVac or BNT162b2) and a booster dose. SARS-CoV-2 anti-spike IgG was measured at least one month after the last vaccine dose using a commercial immunoassay (Abbott SARS-CoV-2 IgG II Quant, CMIA). Results in Arbitrary Units (AU/mL) were converted to WHO standard Binding Antibody Units (BAU/mL) (1 AU/mL = 0.142 BAU/mL). IgG titers >= 7.1 BAU/mL (equivalent to 50 AU/mL) were considered positive. Results: All participants had positive SARS-CoV-2 IgG antibodies. There were no statistically significant differences in IgG levels between HD patients and HCWs at any individual time interval (<3 months, 3-6 months, or >6 months) or in the overall mean titers (HD: 1259 +/- 1112 BAU/mL; HCW: 1002 +/- 765 BAU/mL; p = 0.216). No individual in either group had an IgG titer below 7.1 BAU/mL. Vaccine type, dialysis vintage, and presence of comorbidities did not significantly impact antibody levels. In the HCWs group, those vaccinated only with CoronaVac had significantly lower IgG levels than those receiving only BNT162b2 or a heterologous regimen (CoronaVac followed by BNT162b2). However, among HD patients, IgG levels did not differ by vaccine regimen. Conclusion: HD patients mounted a SARS-CoV-2 IgG antibody response comparable to that of healthy HCWs, with no participant falling below the positivity threshold. Dialysis duration and comorbid conditions did not significantly affect post-vaccination IgG levels. While HCWs who received only CoronaVac showed lower antibody titers than those who received BNT162b2 or a heterologous schedule, this difference was not observed in HD patients. These results suggest that COVID-19 vaccination elicits a robust humoral immune response in the HD population, underscoring the benefit of vaccination in this high-risk group.
